Tesaro, Inc.

Quick facts

Phase 3 pipeline

• Active comparator: Niraparib · Oncology
  Niraparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes, preventing DNA repair in cancer cells and leading to cell death.
• Dostarlimab (TSR-042) · Oncology
  Dostarlimab is a monoclonal antibody that blocks PD-1 on T cells, allowing the immune system to recognize and attack cancer cells.
• Placebo matching dostarlimab · Oncology
  Dostarlimab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and its ligands (PD-L1/PD-L2) on tumor cells, thereby releasing immune checkpoint inhibition and allowing T cells to recognize and attack cancer cells.
• Placebo matching Niraparib · Oncology
  This is a placebo control arm matching the active drug niraparib, a PARP inhibitor that blocks poly(ADP-ribose) polymerase enzymes to prevent DNA repair in cancer cells.

Phase 2 pipeline

• TSR-042

Phase 1 pipeline

• Carboplatin-Nab-Paclitaxel
• Cooperstown Cocktail
• Rolapitant - IV
• Rolapitant - Oral
• TSR-011
• TSR-022
• TSR-033

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Tesaro, Inc. portfolio CI brief
• Tesaro, Inc. pipeline updates RSS